Dr. Hemenway is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2160 South First Avenue
Maywood, IL 60153Phone+1 708-327-3130Fax+1 708-327-3342
Summary
- Dr. Charles Hemenway is a pediatric hematologist/oncologist in Maywood, IL. He received his medical degree from University of Massachusetts Medical School and has been in practice 30 years. He is experienced in general hematologic and oncologic diseases in children. His research focus is fusion oncogene proteins in childhood leukemia.
Education & Training
- Duke University HospitalFellowship, Pediatric Hematology/Oncology, 1991 - 1995
- University of Florida College of MedicineResidency, Internal Medicine/Pediatrics, 1987 - 1991
- University of Massachusetts Medical SchoolClass of 1987
Certifications & Licensure
- LA State Medical License 2022 - 2025
- IL State Medical License 2007 - 2023
- NC State Medical License 1995 - 1998
- FL State Medical License 1989 - 1994
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 1 citationsAn Atypical Presentation of Hodgkin Lymphoma Invading the Myocardium.Heather Kligfeld, Shannon M Wynn, Kristen Hermanson, Tehui Marsha Ma, Eugene Suh
Journal of Pediatric Hematology/oncology. 2023-08-01 - Re-examining a strong recommendation based on low-quality evidence in acute chest syndrome.Charles S Hemenway
Pediatric Blood & Cancer. 2023-05-01 - 1 citationsEmergence of a Ph-negative Clone in a Child With Ph+ ALLCasey J Mehrhoff, Charles S. Hemenway, Eugene Suh
Journal of Pediatric Hematology/oncology. 2020-08-01
Press Mentions
- Children’s Hospital New Orleans Designated for New Sickle Cell Gene TherapyMarch 11th, 2024
- Twenty-Seven Loyola Physicians Named to Chicago Magazine's 2019 Top Cancer DoctorsNovember 6th, 2019
Grant Support
- Structure/Function Of AF9 And MLL-AF9National Cancer Institute2011
- Targeted Therapy For 11Q23 Acute LeukemiasNational Cancer Institute2009–2011
- Disrupting The AF4-AF9 Protein Complex In MLL Leukemias.National Cancer Institute2008–2009
- Tulane Cancer Genetics Cobre: Inovative Therapies For T(4;11) LeukemiaNational Center For Research Resources2004–2008
- Targeted Therapy For 11Q23 Acute Leukemias.National Cancer Institute2004–2007
- BMI1 Interacting Proteins In Neoplastic TransformationNational Cancer Institute1999–2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: